Keyphrases
Parkinson's Disease
100%
Parkinson Patients
25%
Patients with Parkinson's Disease
19%
Ashkenazi Jews
16%
Leucine-rich Repeat Kinase 2 (LRRK2)
13%
Botulinum Toxin Injection
13%
Levodopa-induced Dyskinesia
12%
Familial Mediterranean Fever
10%
Age of Onset
10%
Levodopa
9%
Motor Fluctuations
8%
Healthy Controls
8%
ND0612
8%
Israel
7%
Dyskinesia
7%
Ethnic Groups
6%
Early-late
6%
Multiple Sclerosis
6%
Cerebrotendinous Xanthomatosis
6%
Jewish Patients
6%
HF-rTMS
6%
Subthalamic nucleus Deep Brain Stimulation (STN-DBS)
6%
Unified Parkinson's Disease Rating Scale (UPDRS)
6%
Non-carriers
6%
Botulinum Neurotoxin (BoNT)
6%
LRRK2 G2019S mutation
5%
G2019S mutation
5%
Motor Symptoms
5%
Therapeutic Outcome
5%
Estimated Glomerular Filtration Rate
5%
Neuropsychological Tests
5%
Levodopa-carbidopa
5%
Jewish
5%
Motor Diseases
5%
Mutation Status
5%
Medicine and Dentistry
Parkinson's Disease
40%
Clostridium Botulinum Type A
8%
Cerebrotendinous Xanthomatosis
6%
Spasmodic torticollis
6%
Ataxia
6%
Familial Mediterranean Fever
6%
Infusion
6%
Optic Nerve Atrophy
6%
Diseases
5%
Stereotypic Movement Disorder
5%
Onset Age
5%
